Nuvilex Contracts Fisher BioServices, Inc. for Long-Term Storage of Cells for Future Phase 3 Clinical Trials

SILVER SPRING, MD--(Marketwired - Sep 10, 2013) - Nuvilex, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Fisher BioServices, Inc. for the long-term storage of cells that will be required for its future Phase 3 and other cancer clinical trials.

In order to ensure the safety and availability of cells to be used for its clinical trials, the Company has engaged Fisher BioServices located in Rockville, MD, USA, near Nuvilex's Silver Spring, MD, headquarters. Fisher BioServices, a part of Thermo Fisher Scientific, Inc., an international company traded on the New York Stock Exchange with annual revenues of $13 billion and approximately 39,000 employees, is one of the leading companies in critical biological material management and cell and tissue storage with facilities around the world. This cell storage company adheres to Good Tissue Practice and Good Manufacturing Practice guidelines. Fisher BioServices currently stores more than 170 million biospecimens, including cells and tissues.

The Fisher BioServices facility, located in Rockville, MD, will be used as one of several cell storage sites around the world holding the Nuvilex cancer treatment cells. Multi-site storage of our critically important cells is Standard Operating Procedure for companies, such as Nuvilex, that are engaged in the use of cells for therapeutic purposes.

The cells to be stored in the Fisher BioServices facility both here and abroad are the same cells as those used in the Company's past clinical trials for advanced, inoperable pancreatic cancer. These cells have the ability to activate the well-known anticancer drug ifosfamide. They will be maintained in the facility and can be propagated in the event of a loss in the system somewhere else to obtain cells for encapsulation as needed for clinical trials, including the Company's pancreatic cancer treatment.

Dr. Robert F. Ryan, Nuvilex's President and CEO, commented, "We are glad to be able to engage a leading cell storage company as Fisher BioServices and have them take care of our major long-term cell storage needs. We have designed our storage plans with an intention that as we progress with our preparations, additional cells will be placed there as they are made for future clinical trials. This is a necessary and important step in the Company's efforts toward carrying out our late-stage clinical trials in patients with advanced, inoperable pancreatic cancer."

About Nuvilex
Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.

Safe Harbor Statement:
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.